Page values for "Linaclotide"
From Pharmacopedia
More actions
"Medicines" values
1 row is stored for this page| Field | Field type | Value |
|---|---|---|
| generic | String | Linaclotide |
| brand | String | Linzess |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Guanylate_cyclase_C_agonists|Guanylate cyclase-C agonist]] • [[:Category:IBS_treatments|IBS-C treatment]] |
| mechanism | String | '"`UNIQ--vote-00001197-QINU`"' Extracellular cGMP separately activates submucosal sensory afferents in a way that reduces visceral pain perception, distinguishing linaclotide from purely osmotic laxatives in IBS-C. Diarrhea is the dose-limiting effect'"`UNIQ--ref-00001198-QINU`"'. |
| uses | String | '"`UNIQ--vote-00001199-QINU`"', '"`UNIQ--vote-0000119A-QINU`"', '"`UNIQ--vote-0000119B-QINU`"' |
| starting_dose | String | 145 mcg PO once daily for chronic idiopathic constipation; 290 mcg daily for IBS-C; pediatric 72 mcg daily |
| preparations | String | 72, 145, 290 mcg capsules |
| fda_max | String | 290 mcg/d |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Bowel movement within 1 week; abdominal pain improvement over weeks |
| duration | String | 24 hours |
| halflife | String | Not meaningfully described (negligible systemic absorption — the drug acts locally and is degraded in the GI tract)'"`UNIQ--ref-0000119C-QINU`"' |
| bioavailability | String | Negligible systemic absorption'"`UNIQ--ref-0000119D-QINU`"' |
| pregnancy | String | Limited data; minimal systemic absorption likely renders fetal risk low.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' contraindicating use in children <2 years (lethal dehydration in animal studies)'"`UNIQ--ref-0000119E-QINU`"' |